Incyte: Why Wait For ASCO…Cancer Drug Data Incites Investors

Incyte’s share price is on the rise today after data regarding its new cancer drug released ahead of next month’s ASCO meeting exceeded expectations.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>